Oxford Immunotec Global PLC (OXFD) Analysts See $-0.24 EPS

July 13, 2018 - By Michael Collier

Oxford Immunotec Global PLC (NASDAQ:OXFD) LogoInvestors sentiment decreased to 1.34 in Q1 2018. Its down 0.23, from 1.57 in 2017Q4. It fall, as 9 investors sold Oxford Immunotec Global PLC shares while 20 reduced holdings. 10 funds opened positions while 29 raised stakes. 23.37 million shares or 2.35% less from 23.93 million shares in 2017Q4 were reported.
Deutsche Comml Bank Ag has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Jpmorgan Chase & has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Legal General Gp Public Ltd Company holds 4,803 shares or 0% of its portfolio. Axa reported 580,614 shares. Minnesota-based First Light Asset Management Ltd Liability Com has invested 1.71% in Oxford Immunotec Global PLC (NASDAQ:OXFD). California State Teachers Retirement Sys reported 39,130 shares or 0% of all its holdings. Birchview Capital Lp has 177,303 shares for 1.45% of their portfolio. Endurant Cap Mgmt Limited Partnership owns 0.77% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 165,169 shares. Cortina Asset Mngmt Ltd owns 512,977 shares or 0.31% of their US portfolio. State Bank Of Ny Mellon Corporation has 69,231 shares. Goldman Sachs Group reported 31,340 shares stake. Wells Fargo And Mn invested in 0% or 41,646 shares. Northern has 0% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD). Moreover, Consonance L P has 2.66% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 2.34 million shares. Ellington Mngmt Lc invested in 15,900 shares.

Since February 15, 2018, it had 0 insider buys, and 2 selling transactions for $74,342 activity.

Analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to report $-0.24 EPS on August, 7.They anticipate $0.08 EPS change or 25.00 % from last quarter’s $-0.32 EPS. After having $-0.40 EPS previously, Oxford Immunotec Global PLC’s analysts see -40.00 % EPS growth. The stock increased 0.82% or $0.11 during the last trading session, reaching $13.55. About 43,464 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 0.28% since July 13, 2017 and is uptrending. It has underperformed by 12.29% the S&P500.

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company has market cap of $350.69 million. The Company’s development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. It currently has negative earnings. The firm develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News